Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CURLF NASDAQ:CYTK NASDAQ:KRYS NASDAQ:PRAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCURLFCuraleaf$3.64$9.17$0.72▼$5.05$2.54B1.531.24 million shs1.32 million shsCYTKCytokinetics$71.48-1.1%$69.97$31.99▼$80.20$9.00B0.422.13 million shs1.61 million shsKRYSKrystal Biotech$301.00-2.2%$282.39$127.99▼$319.48$9.07B0.53253,228 shs264,305 shsPRAXPraxis Precision Medicines$254.00-4.1%$324.36$37.19▼$366.52$7.38B2.71445,340 shs570,041 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCURLFCuraleaf-66.67%-65.38%-68.07%-48.29%+41.09%CYTKCytokinetics-1.12%-6.88%-4.49%+18.32%+120.55%KRYSKrystal Biotech-2.21%-2.60%+4.14%+18.65%+127.98%PRAXPraxis Precision Medicines-4.06%-27.42%-24.87%-18.25%+513.97%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCURLFCuraleaf$3.64$9.17$0.72▼$5.05$2.54B1.531.24 million shs1.32 million shsCYTKCytokinetics$71.48-1.1%$69.97$31.99▼$80.20$9.00B0.422.13 million shs1.61 million shsKRYSKrystal Biotech$301.00-2.2%$282.39$127.99▼$319.48$9.07B0.53253,228 shs264,305 shsPRAXPraxis Precision Medicines$254.00-4.1%$324.36$37.19▼$366.52$7.38B2.71445,340 shs570,041 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCURLFCuraleaf-66.67%-65.38%-68.07%-48.29%+41.09%CYTKCytokinetics-1.12%-6.88%-4.49%+18.32%+120.55%KRYSKrystal Biotech-2.21%-2.60%+4.14%+18.65%+127.98%PRAXPraxis Precision Medicines-4.06%-27.42%-24.87%-18.25%+513.97%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCURLFCuraleaf 3.25BuyN/AN/ACYTKCytokinetics 2.86Moderate Buy$99.3038.92% UpsideKRYSKrystal Biotech 2.83Moderate Buy$324.117.68% UpsidePRAXPraxis Precision Medicines 2.95Moderate Buy$572.72125.48% UpsideCurrent Analyst Ratings BreakdownLatest CURLF, PRAX, CYTK, and KRYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026CURLFCuraleaf Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/2/2026PRAXPraxis Precision Medicines TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/2/2026PRAXPraxis Precision Medicines Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$715.00 ➝ $616.006/2/2026PRAXPraxis Precision Medicines OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$750.00 ➝ $650.006/2/2026PRAXPraxis Precision Medicines BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$843.00 ➝ $810.006/2/2026PRAXPraxis Precision Medicines Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$420.00 ➝ $374.006/2/2026PRAXPraxis Precision Medicines WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetUnderperform$166.00 ➝ $162.006/2/2026PRAXPraxis Precision Medicines Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$433.00 ➝ $400.006/2/2026PRAXPraxis Precision Medicines HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$1,245.00 ➝ $1,201.006/1/2026KRYSKrystal Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$310.005/27/2026PRAXPraxis Precision Medicines Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCURLFCuraleaf$1.27B2.01$0.05 per share66.42$1.11 per share3.28CYTKCytokinetics$88.04M101.03N/AN/A($5.39) per share-13.26KRYSKrystal Biotech$389.13M22.80$7.13 per share42.22$42.06 per share7.16PRAXPraxis Precision Medicines$8.55M828.25N/AN/A$34.85 per share7.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCURLFCuraleaf-$231.07M-$0.13N/AN/AN/A-7.76%-8.11%-2.36%N/ACYTKCytokinetics-$784.96M-$6.84N/AN/AN/A-784.02%N/A-52.86%8/6/2026 (Estimated)KRYSKrystal Biotech$204.83M$7.4840.2428.61N/A53.92%19.25%17.62%8/3/2026 (Estimated)PRAXPraxis Precision Medicines-$303.27M-$13.37N/AN/AN/AN/A-43.02%-40.22%8/3/2026 (Estimated)Latest CURLF, PRAX, CYTK, and KRYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026PRAXPraxis Precision Medicines-$3.58-$3.20+$0.38-$3.20$0.10 millionN/A5/5/2026Q1 2026CURLFCuraleaf-$0.24$0.27+$0.51$0.09$316.62 million$324.23 million5/5/2026Q1 2026CYTKCytokinetics-$1.67-$1.67N/A-$1.67$8.52 million$19.36 million5/4/2026Q1 2026KRYSKrystal Biotech$1.45$1.83+$0.38$1.83$112.11 million$116.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCURLFCuraleafN/AN/AN/AN/AN/ACYTKCytokineticsN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCURLFCuraleaf1.051.560.74CYTKCytokineticsN/A4.214.21KRYSKrystal BiotechN/A9.469.06PRAXPraxis Precision MedicinesN/A15.8815.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCURLFCuraleaf0.03%CYTKCytokineticsN/AKRYSKrystal Biotech86.29%PRAXPraxis Precision Medicines67.84%Insider OwnershipCompanyInsider OwnershipCURLFCuraleafN/ACYTKCytokinetics2.60%KRYSKrystal Biotech13.10%PRAXPraxis Precision Medicines2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCURLFCuraleaf5,554698.73 millionN/ANot OptionableCYTKCytokinetics250124.43 million121.20 millionOptionableKRYSKrystal Biotech21029.48 million25.62 millionOptionablePRAXPraxis Precision Medicines11027.88 million27.13 millionOptionableCURLF, PRAX, CYTK, and KRYS HeadlinesRecent News About These CompaniesPraxis Precision Medicines (PRAX) Shares Phase 2/3 POWER1 Study FindingsJune 5 at 7:51 PM | finance.yahoo.comPraxis' Premium Price May Reflect Unrealistic Market Prospects In Essential TremorJune 5 at 4:06 PM | seekingalpha.comPraxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare ConferenceJune 4 at 4:01 PM | globenewswire.comPraxis Precision Medicines (PRAX) Receives a Buy from LifeSci CapitalJune 4 at 7:35 AM | theglobeandmail.comHC Wainwright Issues Pessimistic Outlook for PRAX EarningsJune 4 at 7:14 AM | marketbeat.comGeode Capital Management LLC Acquires 105,347 Shares of Praxis Precision Medicines, Inc. $PRAXJune 4 at 3:47 AM | marketbeat.comWhat is HC Wainwright's Forecast for PRAX FY2030 Earnings?June 3 at 8:39 AM | marketbeat.comPraxis pauses one of its seizure programs after phase 2 failJune 3 at 2:39 AM | fiercebiotech.comFPraxis down on trial setback for seizure therapyJune 3 at 2:39 AM | msn.comPraxis Precision Medicines Faces Vormatrigine Setback And Reassesses Epilepsy PipelineJune 3 at 2:39 AM | finance.yahoo.comThe shocking twist that sent this seizure-focused biotech into a diveJune 3 at 2:39 AM | msn.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2, 2026 | globenewswire.comPraxis Reassesses Vormatrigine Program After Pivotal Epilepsy Study Misses Primary EndpointJune 2, 2026 | benzinga.comPraxis Precision Medicines's Seizure Treatment Fails to Meet Trial's Primary EndpointJune 1, 2026 | marketwatch.comPRAX stock drops 12% after hours on trial setback — retail eyes FDA approval of other pipeline candidatesJune 1, 2026 | msn.comFDA Acceptance of Two CNS NDAs Might Change The Case For Investing In Praxis Precision Medicines (PRAX)June 1, 2026 | finance.yahoo.comPraxis Precision Medicines Shares Fall as Seizure Treatment Fails to Meet Trial's Primary Endpoint -- UpdateJune 1, 2026 | marketwatch.comPraxis Precision's epilepsy drug misses main goal of mid-to-late stage studyJune 1, 2026 | reuters.comPraxis Precision Reassesses Vormatrigine After Mixed POWER1 DataJune 1, 2026 | tipranks.comPraxis Precision Medicines Provides Vormatrigine Program UpdateJune 1, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Eli Lilly & Co (LLY)May 28, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCURLF, PRAX, CYTK, and KRYS Company DescriptionsCuraleaf OTCMKTS:CURLF$3.64 0.00 (0.00%) As of 06/4/2026 03:59 PM EasternCuraleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.Cytokinetics NASDAQ:CYTK$71.48 -0.81 (-1.12%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$71.32 -0.17 (-0.23%) As of 06/5/2026 05:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Krystal Biotech NASDAQ:KRYS$301.00 -6.79 (-2.21%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$303.00 +2.00 (+0.66%) As of 06/5/2026 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Praxis Precision Medicines NASDAQ:PRAX$254.00 -10.75 (-4.06%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$249.52 -4.47 (-1.76%) As of 06/5/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
